155 related articles for article (PubMed ID: 28932295)
21. Value of p16(INK4a) in the diagnosis of low-grade urothelial carcinoma of the urinary bladder in urinary cytology.
Alameda F; Juanpere N; Pijuan L; Lloveras B; Gimeno J; Baró T; Salido M; Serrano S; Lloreta J
Cancer Cytopathol; 2012 Aug; 120(4):276-82. PubMed ID: 22419364
[TBL] [Abstract][Full Text] [Related]
22. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
23. P53 gene mutation and expression of MDM2, P53, P16 protein and their relationship in human glioma.
Cui W; Wu R; Cao H; Gao J; Wang X; Ren Q
J Huazhong Univ Sci Technolog Med Sci; 2005; 25(6):622-4, 635. PubMed ID: 16696307
[TBL] [Abstract][Full Text] [Related]
24. Co-expression of p16 and p53 characterizes aggressive subtypes of ductal intraepithelial neoplasia.
Bechert C; Kim JY; Tramm T; Tavassoli FA
Virchows Arch; 2016 Dec; 469(6):659-667. PubMed ID: 27664050
[TBL] [Abstract][Full Text] [Related]
25. p53 immunohistochemistry in high-grade urothelial carcinoma of the bladder is prognostically significant.
Hodgson A; Xu B; Downes MR
Histopathology; 2017 Aug; 71(2):296-304. PubMed ID: 28342221
[TBL] [Abstract][Full Text] [Related]
26. Genetic alterations of the p16 gene in urothelial carcinoma in Taiwanese patients.
Wu WJ; Kakehi Y; Chang SF; Huang CH; Chang LL
BJU Int; 2000 Jan; 85(1):143-9. PubMed ID: 10619963
[TBL] [Abstract][Full Text] [Related]
27. p16INK4a hypermethylation and p53, p16 and MDM2 protein expression in esophageal squamous cell carcinoma.
Taghavi N; Biramijamal F; Sotoudeh M; Khademi H; Malekzadeh R; Moaven O; Memar B; A'rabi A; Abbaszadegan MR
BMC Cancer; 2010 Apr; 10():138. PubMed ID: 20388212
[TBL] [Abstract][Full Text] [Related]
28. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
[TBL] [Abstract][Full Text] [Related]
29. MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma.
Brunelli M; Tafuri A; Cima L; Cerruto MA; Milella M; Zivi A; Buti S; Bersanelli M; Fornarini G; Vellone VG; Rebuzzi SE; Procopio G; Verzoni E; Bracarda S; Sabbatini R; Baldessari C; Eccher A; Passalacqua R; Perrucci B; Giganti MO; Donini M; Panni S; Tucci M; Prati V; Ortega C; Caliò A; Alongi F; Munari E; Pappagallo G; Iacovelli R; Mosca A; Porta C; Martignoni G; Antonelli A
J Clin Pathol; 2022 Jan; 75(1):39-44. PubMed ID: 33144356
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical expression of the p53, mdm2, p21/Waf-1, Rb, p16, Ki67, cyclin D1, cyclin A and cyclin B1 proteins and apoptotic index in T-cell lymphomas.
Kanavaros P; Bai M; Stefanaki K; Poussias G; Rontogianni D; Zioga E; Gorgoulis V; Agnantis NJ
Histol Histopathol; 2001 Apr; 16(2):377-86. PubMed ID: 11332692
[TBL] [Abstract][Full Text] [Related]
31. p16/Ki-67 dual labeling and urinary cytology results according to the New Paris System for Reporting Urinary Cytology: Impact of extended follow-up.
Piaton E; Advenier AS; Carré C; Decaussin-Petrucci M; Mège-Lechevallier F; Hutin K; Nennig C; Colombel M; Ruffion A
Cancer Cytopathol; 2017 Jul; 125(7):552-562. PubMed ID: 28371465
[TBL] [Abstract][Full Text] [Related]
32. The study of p53 and p16 immunoexpression in serous borderline and malignant ovarian tumors.
Marinaş MC; Mogoş DG; Simionescu CE; Stepan A; Tănase F
Rom J Morphol Embryol; 2012; 53(4):1021-5. PubMed ID: 23303027
[TBL] [Abstract][Full Text] [Related]
33. P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma.
Krüger S; Mahnken A; Kausch I; Feller AC
Eur Urol; 2005 Apr; 47(4):463-7. PubMed ID: 15774242
[TBL] [Abstract][Full Text] [Related]
34. Expression of pRb, p53, p16 and cyclin D1 and their clinical implications in urothelial carcinoma.
Lee K; Jung ES; Choi YJ; Lee KY; Lee A
J Korean Med Sci; 2010 Oct; 25(10):1449-55. PubMed ID: 20890425
[TBL] [Abstract][Full Text] [Related]
35. Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations.
Yu Q; Li Y; Mu K; Li Z; Meng Q; Wu X; Wang Y; Li L
Diagn Pathol; 2014 Mar; 9():71. PubMed ID: 24667108
[TBL] [Abstract][Full Text] [Related]
36. Study of mutated p53 protein by immunohistochemistry in urothelial neoplasm of urinary bladder.
Roychowdhury A; Dey RK; Bandyapadhyay A; Bhattacharya P; Mitra RB; Dutta R
J Indian Med Assoc; 2012 Jun; 110(6):393-6. PubMed ID: 23360043
[TBL] [Abstract][Full Text] [Related]
37. Altered patterns of MDM2 and TP53 expression in human bladder cancer.
Lianes P; Orlow I; Zhang ZF; Oliva MR; Sarkis AS; Reuter VE; Cordon-Cardo C
J Natl Cancer Inst; 1994 Sep; 86(17):1325-30. PubMed ID: 8064890
[TBL] [Abstract][Full Text] [Related]
38. Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of Brenner tumors and transitional cell carcinomas.
Cuatrecasas M; Catasus L; Palacios J; Prat J
Am J Surg Pathol; 2009 Apr; 33(4):556-67. PubMed ID: 19033864
[TBL] [Abstract][Full Text] [Related]
39. A research on the protein expression of p53, p16, and MDM2 in endometriosis.
Sang L; Fang QJ; Zhao XB
Medicine (Baltimore); 2019 Apr; 98(14):e14776. PubMed ID: 30946310
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma.
Chiesa-Vottero AG; Malpica A; Deavers MT; Broaddus R; Nuovo GJ; Silva EG
Int J Gynecol Pathol; 2007 Jul; 26(3):328-33. PubMed ID: 17581420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
